9Bio Therapeutics is a biotech company committed to developing innovative oncology therapeutics. Our AI-guided structural biology platform integrates anatomical and biochemical contexts to design drugs that selectively target tumors. Using this approach, we generate medicines with specificity for tumors that spare healthy tissues, improving safety, efficacy, and opening the door to previously underexploited therapeutic modalities. Our pipeline includes two discovery-stage therapies: an antibody-drug conjugate (ADC) targeting chemoresistant tumor cells and an ADC targeting tumor-subverted immune cells.
Company Details
- Employees
- 5
- Founded
- -
- Address
- 2325 Rue De L'université, La Centrale,canada
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.9bio.ca
- HQ
- Québec, Quebec
9bio Therapeutics Questions
9Bio Therapeutics's website is https://www.9bio.ca
9Bio Therapeutics's LinkedIn profile is https://ca.linkedin.com/company/9bio
9Bio Therapeutics has
5 employees.
View email and phone details for 5
employees at 9Bio Therapeutics.
9Bio Therapeutics's industry is
Biotechnology Research
9Bio Therapeutics's top competitors are
Proxai,
Stoked Bio,
Seragene Therapeutics,
Ability Biotherapeutics,
Kapoose Creek Bio,
Neiges Biotechnologies,
Cerecura Nanotherapeutics,
Vega Bioimaging Technologies Inc.,
Simmunome Inc.,
Aramis Biotechnologies.
9Bio Therapeutics's categories are Biotechnology Research
9Bio Therapeutics's founding year is 2023
